CAMPATH Drug Profile
✉ Email this page to a colleague
Summary for Tradename: CAMPATH
| High Confidence Patents: | 7 |
| Applicants: | 1 |
| BLAs: | 1 |
| Recent Clinical Trials: | See clinical trials for CAMPATH |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for CAMPATH |
Recent Clinical Trials for CAMPATH
Identify potential brand extensions & biosimilar entrants
| Sponsor | Phase |
|---|---|
| Children's Hospital Medical Center, Cincinnati | Phase 2 |
| City of Hope Medical Center | Phase 1 |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
Recent Litigation for CAMPATH
Identify key patents and potential future biosimilar entrants
District Court Litigation
| Case Name | Date |
|---|---|
| AbbVie Inc. v. Hetero USA, Inc. | 2024-08-08 |
| AbbVie Inc. v. Hetero USA, Inc. | 2023-11-20 |
| Janssen Biotech, Inc. v. Amgen Inc. | 2022-11-29 |
PTAB Litigation
| Petitioner | Date |
|---|---|
| Miltenyi Biomedicine GmbH et al. | 2022-04-12 |
| GEMoaB Monoclonals GmbH et al. | 2019-12-20 |
| Forty Seven, Inc. | 2018-01-08 |
Pharmacology for CAMPATH
| Mechanism of Action | CD52-directed Antibody Interactions |
| Established Pharmacologic Class | CD52-directed Cytolytic Antibody |
Note on Biologic Patents
Matching patents to biologic drugs is far more complicated than for small-molecule drugs.
DrugPatentWatch employs three methods to identify biologic patents:
- Brand-side disclosures in response to biosimilar applications
- General brand-side disclosures
- Patents from broad patent text search
These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.
These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
1) High Certainty: US Patents for CAMPATH Derived from Brand-Side Litigation
No patents found based on brand-side litigation
2) High Certainty: US Patents for CAMPATH Derived from Company Disclosures
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Patent No. | Estimated Patent Expiration | Source |
|---|---|---|---|---|---|---|---|
| Genzyme Corporation | CAMPATH | alemtuzumab | Injection | 103948 | ⤷ Sign Up | 2013-08-13 | Company disclosures |
| Genzyme Corporation | CAMPATH | alemtuzumab | Injection | 103948 | ⤷ Sign Up | 2013-08-13 | Company disclosures |
| Genzyme Corporation | CAMPATH | alemtuzumab | Injection | 103948 | ⤷ Sign Up | 2014-08-05 | Company disclosures |
| Genzyme Corporation | CAMPATH | alemtuzumab | Injection | 103948 | ⤷ Sign Up | 2015-12-08 | Company disclosures |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Patent No. | >Estimated Patent Expiration | >Source |
3) Low Certainty: US Patents for CAMPATH Derived from Patent Text Search
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Patent No. | Estimated Patent Expiration | Source |
|---|---|---|---|---|---|---|---|
| Genzyme Corporation | CAMPATH | alemtuzumab | Injection | 103948 | ⤷ Sign Up | 2033-03-11 | Patent claims search |
| Genzyme Corporation | CAMPATH | alemtuzumab | Injection | 103948 | ⤷ Sign Up | 2028-04-10 | Patent claims search |
| Genzyme Corporation | CAMPATH | alemtuzumab | Injection | 103948 | ⤷ Sign Up | 2039-02-26 | Patent claims search |
| Genzyme Corporation | CAMPATH | alemtuzumab | Injection | 103948 | ⤷ Sign Up | 2033-02-08 | Patent claims search |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Patent No. | >Estimated Patent Expiration | >Source |
International Patents for CAMPATH
Supplementary Protection Certificates for CAMPATH
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 122016000041 | Germany | ⤷ Sign Up | PRODUCT NAME: ALEMTUZUMAB; REGISTRATION NO/DATE: EU/1/13/869 20130912 |
| 122008000043 | Germany | ⤷ Sign Up | PRODUCT NAME: CLOSTRIDIUM BOTULINUM NEUROTOXIN TYP A (150KD), FREI VON KOMPLEXPROTEINEN; REGISTRATION NO/DATE: 57093.00.00 20050531 |
| PA2016019,C2066352 | Lithuania | ⤷ Sign Up | PRODUCT NAME: ALEMTUZUMABAS; REGISTRATION NO/DATE: EU/1/13/869 20130912 |
| 253 5012-2016 | Slovakia | ⤷ Sign Up | PRODUCT NAME: ALEMTUZUMAB; REGISTRATION NO/DATE: EU/1/13/869 20130916 |
| >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
